KDI-792: Treatment of diabetic neuropathy thromboxane A2 synthetase inhibitor thromboxane A2 antagonist

Drugs of the Future

Volumn 21, Issue 12, 1996, Pages 1224-1228

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 CHLOROPHENYLSULFONYLAMINO) 1 (3 PYRIDYLMETHYL) 2 PYRROLIDINYL] 5 HEXENOIC ACID; 6 OXOPROSTAGLANDIN F1 ALPHA; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

DIABETIC NEUROPATHY; DRUG BLOOD LEVEL; DRUG SYNTHESIS; DRUG URINE LEVEL; HUMAN; NERVE FUNCTION; ORAL DRUG ADMINISTRATION; PROSTAGLANDIN METABOLISM; SHORT SURVEY; SKIN BLOOD FLOW; SKIN TEMPERATURE;

EID: 3142577013     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.12.378255     Document Type: Article

References (22)

1. Setoi, H., Sawada, A., Tanaka, H., Hashimoto, M. (Fujisawa Pharm Co., Ltd.). Pyrrolidine derivs. AU 8943753, EP 367130, JP 90152960, US 5130323, US 5264453, US 5514701.
2. Kagara, K., Goto, S., Yonishi, S., Ikushima, M., Baba, Y., Horiai, H., Seki, H. (Fujisawa Pharm. Co., Ltd.). Process for producing pyrrolidine deriv. and salt thereof. WO 9401400.
3. Kamijo, T., Hokari, H., Hirata, K., Yanagi, T., Oda, Y. (Kissei Pharm.). Manufacturing method of (5Z)-6-[(2S,4R)-4-(4-chloro-phenylsulfonylamino) - 1 - (3 - pyridylmethyl) - 2 - pyrrolidinyl - 5 hexenoic acid and its intermediates. JP 95291966.
4. Kamijo, T., Hokari, H., Hirata, K., Yanagi, T., Oda, Y. (Kissei Pharm.). Novel pyrrolidine derivs. JP 96012670.
5. Kamijo, T., Hokari, H., Hirata, K., Yanagi, T., Oda, Y. (Kissei Pharm.). Novel pyrrolidine derivs. JP 95291965.
6. 2 and prostacyclin. Pharmacol Rev 1979, 30: 293-331.
7. Ogletree, M.L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc 1987, 46: 133-8.
8. Moncada, S., Gryglewski, R., Bunting, S., Vane, J.R. An enzyme isolated from arteries transforms prostaglandin in endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263: 663-5.
9. Colwell, J.A., Lopes-Virella, M., Halushka, P.V. Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care 1981, 4: 121-33.
10. Colwell, J.A., Halushka, P.V., Sagi, K.E., Sagel, J. Platelet function and diabetes mellitus. Med Clin North Amer 1978, 62: 753-66.
11. Colwell, J.A., Halushka, P.V., Sagi, K.E., Lopes-Virella, M.F., Sagel, J. Diabetic vascular disease. Pathophysiological mechanisms and therapy. Arch Intern Med 1979, 139: 225-30.
12. Sagel, J., Colwell, J.A., Crook, L., Laimins, M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975, 82: 733-8.
13. Colwell, J.A., Winocour, P.D., Halushka, P.V. Do platelets have anything to do with diabetic microvascular disease? Diabetes 1983, 32(Suppl. 2): 14-9.
14. Watanabe, J., Umeda, F., Wasada, T., Ibayashi, H. Effect of prostaglandin synthetase inhibitors on platelet aggregation and thromboxane production in diabetes mellitus. Tohoku J Exp Med 1984, 144: 143-50.
15. Butkus, A., Skrinska, V.A., Schumacher. O.P. Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. Thromb Res 1980, 19: 211-23.
16. Brunner, D., Klinger, J., Weisbort, J., Tuval, M., Nakash, J., Rosenberg, C.H., Nissim, S. Thromboxane, prostacyclin, betathromboglobin, and diabetes mellitus. Clin Ther 1984, 6: 636-42.
17. Harrison, H.E., Reece, A.M., Johnson, M. Decreased vascular prostacyclin in experimental diabetes. Life Sci 1978, 23: 351-6.
18. 1α, a stable metabolite of prostacyclin in diabetes with or without vascular complication. Acta Med Biol 1983, 31: 53-63.
19. Boulton, A.J.M. Pathogenesis of diabetic neuropathy. In: The Diabetes Annual, 7th Edition, S.M. Marshall, P.D. Home, K.G.M.M. Alberti and L.P. Krall (Eds.), Elsevier, Amsterdam, 1993, 192-210.
20. 2 by cultured retinal endothelial cells. Life Sci 1996, 58: 239-43.
21. Uematsu, T., Kosuge, K., Umemura, K., Nakano, M., Terakawa, M., Nakashima, M. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol 1996, 48: 380-5.
22. 2 dual blocker KDI-792. Prostagland Leuk Essent Fatty Acids 1995, 53: 139-45.